The Impact of Peri-operative Anti-TNF Treatment on Anastomosis-Related Complications in Crohn’s Disease Patients. A Critical Review
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Tumor necrosis factor (TNF)α is a cytokine exerting pleiotropic effects on critical cell functions and, most importantly, is the main regulator of pro-inflammatory cytokine production and a key player in the pathophysiology of numerous autoimmune diseases, including Crohn’s disease.
TNFα became a therapeutic target and TNFα blocking agents are currently used in the treatment of inflammatory diseases. Beyond the therapeutic benefits deriving from TNFα neutralization, amendments in the cellular functions of the immune system may as well induce potent immunosuppressive effects. An attenuated immune response may compromise the intestinal healing ability, thus leading to weaker anastomosis and increased risk of anastomotic leak and septic complications.
This hypothesis raises great concerns about the safety of perioperative administration of anti-TNF and has been the endpoint of numerous studies.
The aim of this review is to critically evaluate the evidence regarding the role of TNFα in anastomosis related complications after abdominal surgery in Crohn’s disease patients.
- The Impact of Peri-operative Anti-TNF Treatment on Anastomosis-Related Complications in Crohn’s Disease Patients. A Critical Review
Journal of Gastrointestinal Surgery
Volume 18, Issue 6 , pp 1216-1224
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Wound Healing
- Intestinal anastomoses
- Postoperative complications
- Industry Sectors
- Author Affiliations
- 1. Second Department of Surgery, Aretaieion Hospital, Medical School, University of Athens, Athens, Greece
- 2. Department of Gastroenterology, Tzaneio General Hospital, Zanni & Afentouli 1, 18536, Piraeus, Greece
- 3. Molecular Carcinogenesis Group, Laboratory of Histology and Embryology, School of Medicine, University of Athens, Athens, Greece
- 4. Experimental-Research Unit, ELPEN-Pharmaceuticals Co. Inc, Pikermi Attikis, Greece